Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta‐analysis
Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta‐analysis
复制标题
DOI：
10.1111/jcpt.13570
复制
发表时间：
2021-11
影响因子：
2
通讯作者：
Hong Gong;Yun Su;Lixian Zhao;Li Ma;Liying Zhang;Liangying Hou;Tingting Li;Shiwei Niu;Han Zhang;Chenghao Li;Xiaojie Jin;L. Ge;Guangxian Leng;Yongqi Liu
中科院分区：
文献类型：
--
作者：
Hong Gong;Yun Su;Lixian Zhao;Li Ma;Liying Zhang;Liangying Hou;Tingting Li;Shiwei Niu;Han Zhang;Chenghao Li;Xiaojie Jin;L. Ge;Guangxian Leng;Yongqi Liu
越来越多的靶向药物被用于治疗进展期或转移性胃癌(GC)和胃食道交界癌(GEJC)。然而，这些药物的最佳治疗效果仍存在争议。本研究的目的是系统总结当前靶向药物治疗晚期或转移性GC和GEJC的有效性和安全性。
An increasing number of targeted drugs have been used to treat advanced or metastatic gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, the optimal treatment efficacy of these drugs is still controversial. The aims of this study are to systematically summarize the efficacy and safety of current targeted drugs for advanced or metastatic GC and GEJC.